1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Non Small Cell Lung Cancer Market & Pipeline Insight

Global Non Small Cell Lung Cancer Market & Pipeline Insight

  • January 2015
  • 750 pages
  • ID: 4397236
  • Format: PDF
  • By Kuick Research

Summary

Table of Contents

Lung cancer has become one of the most prevalent cause of cancer related morbidity and mortality in past several decades across the world. Lungs are a pair of spongy tissues present in the thoracic cavity responsible for gaseous exchange from the surrounding environment. These tissues could be easily damaged by the toxins present in environment and cells may show cancerous growth upon longer exposure. The lung cancer is a collective term for cancer development in lungs, it could be divided into two broad categories: Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). It has been observed that NSCLC is the most prevalent type of lung cancer commonly associated with the people practicing the bad habit of cigarette smoking.

Surgery and radiation treatment has been found to have modest effect on NSCL while chemotherapy is largely ineffective due to refractory nature of the cancerous cells. Tumor removal was one of the widely used treatments when effective therapeutics was not available to the patients. Over time, radiation therapy made its place but large number of side effects limited its widespread usage and it was replaced by radiofrequency ablation method which is used to destroy on spot lung tumor cells with the help of high frequency radio waves. Advent of chemotherapeutics medicines helped the patients undergoing surgery or radiation therapy upto limited extent. Targeted therapies came after chemotherapy and they made place in market due to higher safety and efficacy levels.

Targeted therapeutics seems to overtake the NSCLC market due to higher safety and efficacy profiles. Moreover, pharmaceutical companies are promoting them as a replacement for chemotherapeutics which used to dominate in NSCLC therapeutic market. In few cases, combinatorial therapies chemotherapeutics are used with targeted therapeutics but their market share is in decline and this trend is expected to be continued in future. Targeted therapeutics should not be considered as all-in-one treatment as they also have few limitations which are expected to be resolved in near future. The new generation of targeted therapeutics is expected to have refinement at the level of design which will be considered as evolved version of presently available targeted therapeutics.

Advances in monoclonal antibody (mAbs) development technology are expected to evolve further in coming years due to which they may become major NSCLC therapeutic in market. Their potency is expected to increase along with minimum side effects and increase in specificity. The marketing potential of mAbs is expected to increase as they have proven track record and widely accepted by oncologists and patients. The developers of mAbs would consider that the simultaneous evolution of targeted and enzyme inhibitor therapies coupled with other therapies are in developing stages which will give them severe competition after some time. Their market share may get eroded by new NSCLC therapeutics which is likely to provide better pharmacological effect at competitive pricing.

Large clinical development pipeline for NSCLC therapeutics is expected to grow at tremendous rates in coming years. Pharmaceutical companies are investing significant amount of funds in clinical trials which may help large number of patients. But these therapeutics have prove their worth in clinical trials along with statistically significant data on safety and efficacy will be required. They will also take few years in passing regulatory hurdles and marketing authorization before providing medical care to NSCLC patients.



“Global Non Small Cell Lung Cancer Market & Pipeline Insight” Report Highlights:

NSCLC Therapy Market Overview
Mechanism of NSCLC Therapeutics
NSCLC Therapy Market Dynamics: Drivers, Challenges & Future Prospects)
NSCLC Drug Pipeline by Phase, Company & Country
NSCLC Clinical Pipeline: 268 Drugs
Majority of NSCLC Drugs in Phase-II Trials: 99
Marketed NSCLC Drugs: 30

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

  • $ 4750
  • October 2019

The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1, 2019. Conference highlights included new data from PARP inhibitors in ...

Mucin 1 - Pipeline Review, H2 2019

Mucin 1 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Mucin 1 - Pipeline Review, H2 2019SummaryMucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial ...

Bcl 2 Like Protein 1 - Pipeline Review, H2 2019

Bcl 2 Like Protein 1 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Bcl 2 Like Protein 1 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Pipeline Review, H2 2019’; Bcl ...


ref:plp2015

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on